Spider venom peptide trialled as cardiovascular treatment
A potential treatment for heart attack and stroke derived from spider venom has been administered to the first participants in clinical trial.
A team of researchers from the University of Queensland, Australia published preclinical analysis showing the protein Hi1a could treat heart attack and stroke patients. The protein is unique, however, because it derives from the venom of a K’gari funnel web spider.
“We believe that Hi1a could reduce damage to the heart and brain during heart attacks and strokes by preventing cell death caused by lack of oxygen,” said Professor Glenn King from UQ’s Institute for Molecular Science.
“We established that Hi1a is effective at protecting the heart and a subsequent study put it through a series of preclinical tests to mimic real-life treatment scenarios.”
Following the findings, biotechnology company Infensa Bioscience transformed Hi1a into a miniaturised peptide, called IB409, suitable for drug development. A Phase I study is now assessing the safety, tolerability and dosage of IB409.
“If the Phase I and subsequent clinical trials of IB409 show that it can safely and effectively treat heart attacks, we could improve the lives of millions of people living with heart disease around the world,” said Professor Mark Smythe, Infensa CEO and UQ researcher.
The Phase I trial is funded by a $17.8 million grant from the Australian government’s Medical Research Future Fund (MRFF), and philanthropic support from the Victor Chang Cardiac Research Institute and St Vincent’s Hospital, Sydney.
Bruno Quinney, Content Team, DDW
